A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2018
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SMART-C
- 19 Sep 2018 Planned End Date changed from 1 Nov 2018 to 1 Feb 2019.
- 19 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
- 21 Aug 2018 Status changed from recruiting to active, no longer recruiting.